Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Wendy Fasano

Physician Assistant Mesquite, TX Physician Assistant

NPI 1073094975 CMS profile 10689842

1519 N Town East Blvd Ste 100, Mesquite, TX 75150

Open in the dashboard

General payments

$11,698

638 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wendy Fasano of Mesquite, TX is reported in the CMS Open Payments database as having received $11,698 across 638 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,946 114
2024 General $1,803 103
2023 General $1,725 98
2022 General $3,178 133
2021 General $3,046 190

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wendy Fasano
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Wendy Fasano were reported at $1,946. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Wendy Fasano Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,046 $132 $37–$438 $132
2022 $3,178 $155 $48–$522 $149
2023 $1,725 $167 $52–$557 $160
2024 $1,803 $178 $55–$600 $164
2025 $1,946 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,252 65 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,138 60 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $1,013 8 payments
  4. Lilly USA, LLC $881 68 payments
  5. Amgen Inc. $703 37 payments
  6. AstraZeneca Pharmaceuticals LP $702 35 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $670 59 payments
  8. GlaxoSmithKline, LLC. $667 46 payments
  9. Pfizer Inc. $593 33 payments
  10. AbbVie, Inc. $453 34 payments
  11. Other $3,626 193 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,786 635 payments
  2. Consulting Fee $800 1 payment
  3. Education $112 2 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT $1,043 10 payments
  2. JARDIANCE Diabetes $758 39 payments
  3. RYBELSUS $692 36 payments
  4. Kerendia $670 59 payments
  5. Ozempic $668 36 payments
  6. FARXIGA $533 25 payments
  7. TRELEGY ELLIPTA $436 29 payments
  8. JARDIANCE Diabetes $416 34 payments
  9. QUVIVIQ $416 17 payments
  10. UBRELVY $350 28 payments
  11. Other $8,741 504 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 84 drugs

Part D claims

3,201

Median for Physician Assistant: 241

Drug cost

$290,798

Median for Physician Assistant: $4,110

Branded share of claims

21%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 37 $64,680
Jardiance Empagliflozin Brand 63 $55,906
Ozempic Semaglutide Brand 52 $54,205
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 17 $18,446
Januvia Sitagliptin Phosphate Brand 18 $17,814
Eliquis Apixaban Brand 12 $16,282
Myrbetriq Mirabegron Brand 15 $15,716
Farxiga Dapagliflozin Propanediol Brand 15 $13,234
Symbicort Budesonide/Formoterol Fumarate Brand 14 $4,485
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 14 $2,184

The 10 drugs with the highest cost, of 84 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$15,465

Of which drugs: $2,487

Medicare patients

103

Average age 74

Services billed

402

68 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 45%
Arthritis 34%
Ischemic heart disease 27%
Chronic kidney disease 23%
Cancer 19%
Osteoporosis 17%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $173
  • Lilly USA, LLC $80
$253 63 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $176
$176 — —
MOUNJARO
  • Lilly USA, LLC $91
$91 37 —
ZEPBOUND
  • Lilly USA, LLC $90
$90 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $66
$66 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

638 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record